Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Dipna Pharma
Join Channel
Consolidated Standalone

Dipna Pharma.

₹9 0.1 | 1.4%

Market Cap ₹11 Cr.

Stock P/E

P/B 0.6

Current Price ₹9

Book Value ₹ 15.2

Face Value 10

52W High ₹24.1

Dividend Yield 0%

52W Low ₹ 8

Edit Ratio

Dipna Pharma. Research see more...

Overview Inc. Year: 2011Industry: Trading

Dipna Pharma. Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Dipna Pharma. Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Dipna Pharma. Profit & Loss

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 17 20 31 31 73 100
Other Income 0 0 0 0 0 0
Total Income 17 20 31 31 73 100
Total Expenditure 16 20 30 31 70 97
Operating Profit 0 0 0 0 2 3
Interest 0 0 0 0 1 1
Depreciation 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 2 1
Provision for Tax 0 0 0 0 0 0
Profit After Tax 0 0 0 0 1 1
Adjustments 0 0 0 0 0 0
Profit After Adjustments 0 0 0 0 1 1
Adjusted Earnings Per Share 3 1.6 2.9 1.2 57.1 0.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 37% 48% 43% 0%
Operating Profit CAGR 50% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -32% NA% NA% NA%
ROE Average 7% 37% 26% 24%
ROCE Average 10% 10% 9% 9%

Dipna Pharma. Balance Sheet

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 0 0 1 1 2 24
Minority's Interest 0 0 0 0 0 0
Borrowings 0 0 3 4 6 14
Other Non-Current Liabilities 0 0 0 0 0 -0
Total Current Liabilities 11 14 15 21 29 39
Total Liabilities 11 14 18 25 36 78
Fixed Assets 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0 0
Total Current Assets 11 14 18 25 36 78
Total Assets 11 14 18 25 36 78

Dipna Pharma. Cash Flow

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 0 0 0 0
Cash Flow from Operating Activities 0 0 -3 -2 3 -21
Cash Flow from Investing Activities 0 0 0 0 -0 -0
Cash Flow from Financing Activities 0 0 3 3 -3 26
Net Cash Inflow / Outflow 0 0 0 0 -0 5
Closing Cash & Cash Equivalent 0 0 0 0 0 6

Dipna Pharma. Ratios

# Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 2.96 1.57 2.89 1.18 57.07 0.63
CEPS(Rs) 3.01 2.02 3.32 1.54 57.37 0.63
DPS(Rs) 0 0 0 0 0 0
Book NAV/Share(Rs) 22.32 23.89 26.78 27.96 85.03 16.72
Core EBITDA Margin(%) 2.32 2.4 1.47 1.29 3.1 2.51
EBIT Margin(%) 2.4 2.38 1.47 1.32 3.11 2.5
Pre Tax Margin(%) 0.43 0.27 0.2 0.18 2.16 1.38
PAT Margin (%) 0.37 0.16 0.19 0.08 1.6 0.91
Cash Profit Margin (%) 0.37 0.21 0.22 0.1 1.61 0.92
ROA(%) 0.55 0.25 0.36 0.11 3.82 1.6
ROE(%) 13.24 6.78 11.39 4.32 101.02 6.99
ROCE(%) 7.16 7.98 5.42 3.54 18.16 9.58
Receivable days 132.26 134.26 119.82 153.94 105.16 101.37
Inventory Days 95.86 69.48 53.12 75.05 33.86 46.11
Payable days 141.56 128.29 99.9 123.97 92.66 113.36
PER(x) 0 0 0 0 0 16.47
Price/Book(x) 0 0 0 0 0 0.62
Dividend Yield(%) 0 0 0 0 0 0
EV/Net Sales(x) 0.29 0.29 0.31 0.39 0.14 0.25
EV/Core EBITDA(x) 12.14 12.08 20.53 29.28 4.41 10.05
Net Sales Growth(%) 0 21.9 51.32 1.51 134.7 37.35
EBIT Growth(%) 0 20.88 -6.41 -9.02 452.31 10.5
PAT Growth(%) 0 -47 84.23 -58.98 4721.77 -21.85
EPS Growth(%) 0 -47 84.23 -58.98 4721.77 -98.9
Debt/Equity(x) 11.18 12.31 17.48 21.74 5.86 0.65
Current Ratio(x) 1.04 1.03 1.27 1.21 1.26 1.99
Quick Ratio(x) 0.63 0.79 0.88 0.85 1.04 1.5
Interest Cover(x) 1.22 1.13 1.15 1.16 3.29 2.23
Total Debt/Mcap(x) 0 0 0 0 0 1.06

Dipna Pharma. Shareholding Pattern

# Sep 2022 Mar 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 66.56 66.56 57.19 9.98 9.98
FII 0 0 0 0 0
DII 0 0 0 0 0
Public 33.44 33.44 42.81 90.02 90.02
Others 0 0 0 0 0
Total 100 100 100 100 100

Pros

  • Stock is trading at 0.6 times its book value
  • Company has a good return on equity (ROE) track record: 3 Years ROE 37%

Cons

  • Promoter holding is low: 9.98%.
  • Debtor days have increased from 92.66 to 113.36days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Dipna Pharma. News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!